Trial · NCT03274882
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) rate | at 2 months | percentage of patients alive without investigator-assessed radiological disease progression according to RECIST 1.1 after 2 months |
| Secondary | Progression-Free Survival (PFS). | Through study completion, an average of 12 weeks | based on Investigator review of the images according to RECIST 1.1 |
| Secondary | Overall Response Rate (ORR). | Through study completion, an average of 12 weeks | based on Investigator review of the images according to RECIST 1.1 |
| Secondary | Disease Control Rate (DCR) | Through study completion, an average of 12 weeks | based on Investigator review of the images according to RECIST 1.1 |
| Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in laboratory tests (haematology, blood biochemistry and urinalysis) [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in physical examination and performance status (ECOG) [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in blood pressure [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in heart rate [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in body temperature [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in respiration rate [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in body weight [safety and tolerability] | Through study completion, an average of 12 weeks | |
| Secondary | Abnormalities in 12-leads ECG parameters [safety and tolerability] | Through study completion, an average of 12 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03274882/registered